about
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesThe pharmacological landscape and therapeutic potential of serine hydrolasesActivity-based proteomic and metabolomic approaches for understanding metabolismExpression of peptidylarginine deiminase 4 in an alkali injury model of retinal gliosis.A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs.Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platformsChemical proteomics and its impact on the drug discovery process.Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening.Discovery of halopyridines as quiescent affinity labels: inactivation of dimethylarginine dimethylaminohydrolaseAutodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity.Inhibiting AMPylation: a novel screen to identify the first small molecule inhibitors of protein AMPylation.Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.Screening for dimethylarginine dimethylaminohydrolase inhibitors reveals ebselen as a bioavailable inactivatorActivity-based protein profiling of protein arginine methyltransferase 1.Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment methodChemical biology of protein arginine modifications in epigenetic regulationProtein Arginine Methylation and Citrullination in Epigenetic RegulationChemical approaches to study metabolic networksActivity-based probes for the study of proteases: recent advances and developments.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivationPAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis.PAD2 Activity Monitored via a Fluorescent Substrate Analog.From covalent glycosidase inhibitors to activity-based glycosidase probes.Role of citrullination modification catalyzed by peptidylarginine deiminase 4 in gene transcriptional regulation.Fluorescence polarization assays in high-throughput screening and drug discovery: a reviewNovel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization.Fluorescence-based monitoring of PAD4 activity via a pro-fluorescence substrate analog.Monitoring of protein arginine deiminase activity by using fluorescence quenching: multicolor visualization of citrullination.Facile fluorescence-based detection of PAD4-mediated citrullination.Novel furan-containing peptide-based inhibitors of protein arginine deiminase type IV (PAD4).Advanced Activity-Based Protein Profiling Application Strategies for Drug Development.Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor
P2860
Q26829985-BA8A3ACE-C343-457F-A317-3F288FBF972DQ26995817-2A626775-9AD0-4CC8-A8E7-AE719A568D9FQ30405653-661B4663-BA18-48CC-B029-444DE5BA3812Q33850388-807A21BE-7185-4C47-A63F-E40C1647BA5EQ33939476-FDD6B349-2432-4D07-ADF5-5AC78EB49565Q34228026-D52244F5-1EA5-42E0-8A41-9BE5F6007782Q34342900-33A4CF59-4767-4CBB-8F90-5B7636DE403CQ34530440-A88A3D38-6ADD-4C5E-9BE6-6E1ED2A741A8Q34572283-2446CCC7-A675-44FC-AB65-C33E22683F4AQ34969938-F5BC728E-1033-429D-89E9-114821C82B1EQ35052423-CEF1F1BA-6AB1-4B2F-80C4-878F1874DDB2Q35060808-9DAD585E-AFBB-4DE9-B90B-B72528F074E8Q35131941-563FB7EA-A03A-48EA-8869-3E7FC45A9BC5Q35209771-289506F7-4DCF-4465-ADC9-2ACF34E66DBDQ35420805-4166FA60-9276-402C-A112-74182E51A0FFQ35572208-EC38CD33-06FD-4DE5-AFFA-A60E8D9389E4Q35722457-931AB525-595B-4DB0-8EBE-FD184FC2AFB7Q36713555-3AFF8EB5-9899-4940-A32A-9F13CD8B1FEEQ37019550-20A7F9D8-DCAD-4629-897B-9E2C48C70166Q37995130-4CE47352-1032-465F-B484-99409FB3361BQ38233723-36521E2E-2BCC-4349-AE81-0703C849CC0DQ38280544-2F17BFA1-839D-4BE8-A6FB-D0B10A0CA125Q38747640-F2F5E757-8A88-40E7-81B9-2B230CFB68C0Q39044218-70D1A13C-C0AC-4AED-94D9-8862CFBC8D24Q39147865-B242414F-CF44-4C20-944F-F1A89A75AC55Q39283898-D2C26B2D-21A9-46D0-8F59-E23D0819FFF3Q41467248-07B780E2-7269-49CE-A3AF-36BA4E956ED0Q41789076-08AF150A-691D-4597-8AA5-C30E226E80E9Q41893154-5F566016-3EB2-4B69-83D4-FE3C3975B40FQ42022565-BBD3585C-2E72-4DAA-B42A-97C28D4DD731Q44046731-411494E4-288E-4C9D-8CBB-78BD615B5D2BQ48329143-F941823A-81EB-46AE-9AE7-10A9A407A5FBQ52311693-02798615-2048-476D-8C8B-1B96BE5E051DQ57822200-08247271-1F25-4393-8241-72FA6E143E03
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@ast
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@en
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@nl
type
label
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@ast
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@en
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@nl
prefLabel
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@ast
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@en
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@nl
P2093
P2860
P356
P1476
A fluopol-ABPP HTS assay to identify PAD inhibitors.
@en
P2093
Bryan Knuckley
Corey P Causey
Daniel A Bachovchin
Hugh Rosen
Jessica Slack
Justin E Jones
Paul R Thompson
Steven J Brown
P2860
P304
P356
10.1039/C0CC02634D
P407
P577
2010-08-25T00:00:00Z